Home Blog of Signal Transduction PI3K/Akt/mTOR PI3K

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

PI3K

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

5 views | Jun 27 2022

Motahareh Mortazavi et al. reported that whole-genome analyses demonstrated the frequent involvement of aberrant activations of PI3K/AKT/mTOR pathway components in PDAC patients. [Read the Full Post]

A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease

10 views | Jun 24 2022

Geru Tao et al. found that inhalation of hydrogen/oxygen improved serum lipid and liver enzymes. [Read the Full Post]

ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway

71 views | Jun 10 2022

Jufeng Sun et al. thought that ARHGAP9 inhibited the malignant phenotypes of CRC cells via interdicting PI3K/AKT/mTOR signaling pathway. [Read the Full Post]

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells

38 views | May 30 2022

Manuela Piazzi et al. indicated that BYL-719, either alone or in combination with the p110δ inhibitor, CAL-101, could represent an efficient treatment for human rhabdomyosarcoma presenting with aberrant upregulation of the PI3K signaling pathway. [Read the Full Post]

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma

27 views | May 29 2022

Ziyue Gu et al. provided insights into the systematic combinatory effect associated with CDK4/6 inhibition and supported further initiation of clinical trials using the palbociclib plus alpelisib combination in HPVneg HNSCC with PIK3CA alterations. [Read the Full Post]

Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review

58 views | May 05 2022

Jeanne Allard et al. thought high incidence rate of G-TMA was observed in the cohort due to a potential drug interaction between nab-paclitaxel and gemcitabine with an increased risk of developing G-TMA. [Read the Full Post]

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells

195 views | Apr 01 2022

Alessio Malacrida et al. thought that rigosertib could be a potential therapeutic option, alone or in combination with radiations, for nonresectable patients with cholangiocarcinoma. [Read the Full Post]

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair

174 views | Mar 31 2022

Alessio Malacrida et al. hypothesized the mechanism of the action of Rigosertib against cholangiocarcinoma EGI-1 cells, highlighting the importance of proteins involved in the regulation of cell cycles. [Read the Full Post]

DNA repair protein DNA-PK protects PC12 cells from oxidative stress-induced apoptosis involving AKT phosphorylation

147 views | Mar 30 2022

Alessio Cardinale et al. found that DNA-PK could protect cells from oxidative stress induced-apoptosis independently from its function of DSB repair enzyme. [Read the Full Post]

A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors

61 views | Mar 16 2022

Atish D Choudhury et al. showed preliminary evidence of limited anti-tumor activity by imaging and, in prostate cancer, PSA reduction. [Read the Full Post]